within Pharmacolibrary.Drugs.ATC.C;

model C04AF01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.030000000000000002,
    adminDuration  = 600,
    adminMass      = 0.02,
    adminCount     = 1,
    Vd             = 0.0002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Kallidinogenase is an enzyme derived from animal pancreas, used primarily in certain Asian countries to treat peripheral vascular diseases and cerebrovascular disorders by facilitating vasodilation through the kinin–kallikrein system. It is not widely approved or used in the United States or Europe for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for kallidinogenase in humans have not been reported in peer-reviewed publications. The following are estimated parameters based on general enzyme characteristics and dose regimens reported in clinical and therapeutic product information.</p><h4>References</h4><ol><li><p>Cohn, DM, et al., &amp; Longhurst, HJ (2025). CRISPR-Based Therapy for Hereditary Angioedema. <i>The New England journal of medicine</i> 392(5) 458–467. DOI:<a href=&quot;https://doi.org/10.1056/NEJMoa2405734&quot;>10.1056/NEJMoa2405734</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39445704/&quot;>https://pubmed.ncbi.nlm.nih.gov/39445704</a></p></li><li><p>Dorff, T, et al., &amp; Tran, B (2024). A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> 30(8) 1488–1500. DOI:<a href=&quot;https://doi.org/10.1158/1078-0432.CCR-23-2978&quot;>10.1158/1078-0432.CCR-23-2978</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38300720/&quot;>https://pubmed.ncbi.nlm.nih.gov/38300720</a></p></li><li><p>Lim, EA, et al., &amp; Hansen, AR (2023). Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical genitourinary cancer</i> 21(3) 366–375. DOI:<a href=&quot;https://doi.org/10.1016/j.clgc.2023.02.010&quot;>10.1016/j.clgc.2023.02.010</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36948922/&quot;>https://pubmed.ncbi.nlm.nih.gov/36948922</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C04AF01;
